In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
Funding innovation under pressure: examining the role of commercial health insurance in Europe
Europe’s health systems are facing growing pressure amidst strained public budgets, ageing populations, and increasing treatment costs, prompting urgent questio